EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 25 April 2024

Strong intellectual property is critical to competitive edge

By Nathalie Moll, Director General, EFPIA

EU IP policies are weakening the competitive edge at the very moment

that EU leaders have recognised the importance of restoring the region’s

status as a global economic superpower.

As an industry, we echo the call by European heads of state for a new European Competitiveness Deal.

Considering the sector contributes more to the positive EU trade balance than any other, a dedicated health and life sciences strategy should be an integral part of the EU’s industrial strategy.

Critical Medicines Alliance: A positive collaboration to enhance medicines supply chain security...
25 April 2024

EFPIA will work within the Alliance to help build resilience through a number of recommendations Read more

EFPIA Statement on the use of AI in the medicinal product lifecycle in the context of the AI...
22 April 2024

It is critical that the regulatory frameworks governing the use of AI in research, development and manufacture must... Read more

EFPIA swings behind Council’s call for a European Competitiveness Deal
19 April 2024

Time to close the gap Read more

Rare Disease Moonshot: breaking down barriers to accelerate research

The Rare Disease (RD) Moonshot was set up to boost public private collaborations in the areas where there are no treatment options and there is no R&D going on.

The RD Moonshot partners put together three sets of recommendations to highlight where public-private collaborations can add most value.

Click here to learn more on the recommendations for optimising rare disease diagnosis.

Events

International 3Rs prize
01 May 2024 (Deadline is 1 May 2024)

An annual prize awarded for a paper that describes outstanding and original work that has or could have major impacts... Read more

Thought Leader Session: Collaborating for Change
03 May 2024 (Online session)

Transforming Rare Disease Outcomes through Public-Private Partnerships. Read more

What we are reading

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
On 18 April 2024 (Pink Sheet)

Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical... Read more

The clock is ticking on Europe’s competitiveness
On 17 April 2024 (Euractiv)

We are at a critical juncture for the future of health in Europe, where the decisions we make today will have consequences... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu